KR950011443A - 갈란타민 유도체, 이의 제조방법 및 약제로서의 이의 용도 - Google Patents

갈란타민 유도체, 이의 제조방법 및 약제로서의 이의 용도 Download PDF

Info

Publication number
KR950011443A
KR950011443A KR1019940026303A KR19940026303A KR950011443A KR 950011443 A KR950011443 A KR 950011443A KR 1019940026303 A KR1019940026303 A KR 1019940026303A KR 19940026303 A KR19940026303 A KR 19940026303A KR 950011443 A KR950011443 A KR 950011443A
Authority
KR
South Korea
Prior art keywords
hydrogen
compound
formula
alkylcarbonyloxy
alkyl
Prior art date
Application number
KR1019940026303A
Other languages
English (en)
Other versions
KR0169114B1 (ko
Inventor
더블유. 코슬리 2세 레이몬드
데이비스 래리
타베나 베로니카
Original Assignee
제롬 로젠스톡
훽스트-러셀 파마슈티칼즈 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제롬 로젠스톡, 훽스트-러셀 파마슈티칼즈 인코포레이티드 filed Critical 제롬 로젠스톡
Publication of KR950011443A publication Critical patent/KR950011443A/ko
Application granted granted Critical
Publication of KR0169114B1 publication Critical patent/KR0169114B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

본 출원은 콜린성 기능 감퇴에 의해 특징지워지는 기억 기능 장애를 치료하는데 유용한 하기 일반식(I)의 화합물, 당해 화합물을 함유하는 약제학적 조성물 및 당해 화합물의 제조 및 사용방법에 관한 것이다.
상기식에서, R1, R2, R3및 R4는 본 명세서에서 정의한 바와 같다.

Description

칼란타민 유도체, 이의 제조방법 및 약제로서의 이의 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (9)

  1. 일반식(I)의 화합물 및 이의 모든 기하이성체, 광학이성체 및 입체이성체, 또는 약제학적으로 허용되는 이의 부가염.
    상기식에서, R1은 수소, (C1-C12)알킬카보닐, (C1-C12)알콕시카보닐, 모노(C1-C12)알킬아미노카보닐 또는 디(C1-C8)알킬아미노카보닐이고, R2는 수소, (C3-C12)알케닐카보닐옥시, (C3-C12)사이클로 알킬카보닐옥시, (C3-C12)사이클로알킬아미노카보닐옥시, (C3-C12)알키닐카보닐옥시, (C3-C12)사이클로알킬(C1-C12)알킬카보닐옥시, 산소 함유 헤테로사이클릴옥시, 산소 함유 헤테로사이클릴카보닐옥시, 황 함유 헤테로사이클릴옥시, 황 함유 헤테로사이클릴카보닐옥시, 질소 함유 헤테로 사이클릴옥시, 질소 함유 헤테로사이클릴카보닐옥시, 할로알킬설포닐옥시 또는 (C1-C6)알킬실릴옥시이며, R3은 수소, 할로 또는 (C1-C4)알킬이고, R4는 수소 또는 (C1-C6)알킬이며, 단 R3및 R4가 수소인 경우, R1및 R2는 둘 다 수소가 아니다.
  2. 제1항에 있어서, R1이 수소, (C1-C12)알킬카보닐 또는 (C1-C12)알콜시카보닐이고, R2가 수소, (C3-C12)알케닐카보닐옥시, (C3-C12)알키닐카보닐옥시, (C3-C12)사이클로알킬카보닐옥시, (C3-C12)사이클로알킬아미노카보닐옥시, (C3-C12)사이클로알킬 (C1-C12)알킬카보닐옥시, 할로(C1-C6)알킬설포닐옥시, (C1-C6)알킬실릴옥시, 피리딜옥시, 티오모르폴리노카보닐옥시, 푸라닐카보닐옥시, 티에닐카보닐옥시, 테트라하이드로푸라닐카보닐옥시, 푸라닐옥시, 티에닐옥시, 피를리디닐카보닐옥시, 테트라하이드로푸라닐옥시, 피페리디닐카보닐옥시, 아제핀카보닐옥시, 모르폴리노카보닐옥시 또는 테트라하이드로이소퀴놀리닐카보닐옥시이며, R3이 수소 또는 할로이고, R4가 수소 또는 (C1-C6)알킬이며, 단 R3및 R4가 수소인 경우 R1및 R2는 둘 다 수소가 아닌 일반식(I)의 화합물 및 이의 모든 기하이성체, 광학이성체 및 입체이성체, 또는 약제학적으로 허용되는 이의 부가염.
  3. 제1항에 있어서, R1이 수소, (C1-C12)알킬카보닐 또는 (C1-C12)알콕시카보닐옥시, R2가 (C3-C12)알케닐카보닐옥시, (C3-C12)알키닐카보닐옥시, (C3-C12)사이클로알킬카보닐옥시, (C3-C12)사이클로알킬(C1-C12)알킬카보닐옥시, 피리딜옥시, 푸라노일옥시, 모르폴리노카보닐옥시 또는 테트라하이드로이소퀴놀릴카보닐옥시이며, R3이 수소 또는 브롬이고, R4가 수소 또는 메틸인 일반식(I)의 화합물.
  4. 제3항에 있어서, R1이 수소인 일반식(I)의 화합물.
  5. 제4항에 있어서, R3및 R4가 수소인 일반식(I)의 화합물.
  6. 제항에 있어서, R2가 사이클로프로필카보닐옥시, 사이클로부틸카보닐옥시, 사이클로헥실카보닐옥시, 메틸사이클로헥실카보닐옥시, 아다만틸카보닐옥시, 아다만틸메틸카보닐옥시, 2-메틸프로페닐카보닐옥시, 2-프로피닐카보닐옥시, 사이클로헵틸아미노카보닐옥시, 사이클로헥실아미노카보닐옥시, 모르폴리노카보닐옥시 또는 테트라하이드로이소퀴놀리닐카보닐옥시인 일반식(I)의 화합물.
  7. 제1항에 있어서, (6-0-데메틸)-6-0-(1,2,3,4-테트라하이드로이소퀴놀린-2-일)카보닐)갈란타민 또는 약제학적으로 허용되는 이의 산 부가염인 화합물.
  8. 제1항에서 정의한 일반식(I)의 화합물 및 약제학적으로 허용되는 이의 산 부가염을 포함하는 약제학적 조성물.
  9. 콜린성 기능 감퇴에 의해 특징지워지는 기억 기능 장애의 치료에 사용하기에 유용한 약제를 제조하기 위한, 제1항에서 정의한 일반식(I)의 화합물의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019940026303A 1993-10-15 1994-10-14 갈라타민 유도체 및 이를 포함하는 약제학적 조성물 KR0169114B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8/137,440 1993-10-15
US08/137,440 1993-10-15
US08/137,440 US6323195B1 (en) 1993-10-15 1993-10-15 Galanthamine derivatives as acetylcholinesterase inhibitors

Publications (2)

Publication Number Publication Date
KR950011443A true KR950011443A (ko) 1995-05-15
KR0169114B1 KR0169114B1 (ko) 1999-01-15

Family

ID=22477446

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940026303A KR0169114B1 (ko) 1993-10-15 1994-10-14 갈라타민 유도체 및 이를 포함하는 약제학적 조성물

Country Status (23)

Country Link
US (2) US6323195B1 (ko)
EP (2) EP0653427B1 (ko)
JP (1) JP2664344B2 (ko)
KR (1) KR0169114B1 (ko)
CN (1) CN1039911C (ko)
AT (1) ATE212348T1 (ko)
AU (1) AU696249B2 (ko)
CA (1) CA2118174C (ko)
CZ (1) CZ287071B6 (ko)
DE (1) DE69429708T2 (ko)
DK (1) DK0653427T3 (ko)
EG (1) EG20472A (ko)
ES (1) ES2171428T3 (ko)
FI (1) FI108723B (ko)
IL (1) IL111274A (ko)
NO (1) NO310415B1 (ko)
NZ (1) NZ264683A (ko)
PL (1) PL177730B1 (ko)
PT (1) PT653427E (ko)
RO (1) RO114133B1 (ko)
RU (1) RU2114850C1 (ko)
TW (1) TW363969B (ko)
ZA (1) ZA948062B (ko)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9514821D0 (en) * 1995-07-19 1995-09-20 Sod Conseils Rech Applic Galanthamine derivatives
AT403803B (de) * 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
JP5558648B2 (ja) 1998-11-23 2014-07-23 デイビス、ボニー アセチルコリンエステラーゼ阻害剤のための投与製剤
PT1140105E (pt) 1998-12-24 2004-03-31 Janssen Pharmaceutica Nv Composicao de galantamina de libertacao controlada
US8603546B2 (en) * 1999-01-11 2013-12-10 Herbaceuticals Inc. Herbal supplement for increased muscle strength and endurance for athletes
ATE355066T1 (de) * 1999-01-11 2006-03-15 Atanas Russinov Djananov Nahrungszusatz aus kräutern zur steigerung der muskulären kraft und ausdauer von athleten
WO2000059544A1 (fr) * 1999-03-31 2000-10-12 Eisai Co., Ltd. Compositions stabilisees contenant des medicaments nootropes
KR100502391B1 (ko) * 1999-10-26 2005-07-19 얀센 파마슈티카 엔.브이. 갈란타민 및 감미제를 함유하는 경구 용액
CA2393301A1 (en) * 1999-12-10 2001-06-21 Bonnie Davis Analogs of galanthamine and lycoramine as modulators of nicotinic receptors
EP1181294B1 (de) 2000-03-31 2004-03-31 Sanochemia Pharmazeutika Aktiengesellschaft Neue derivate und analoga von galanthamin
US20030162770A1 (en) * 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
WO2005065661A2 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Immediate, controlled and sustained release formulations of galanthamine
WO2005065662A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Solid dosage formulations of galantamine
WO2006004201A1 (ja) * 2004-07-01 2006-01-12 Eisai R & D Management Co., Ltd. 神経再生促進剤
EP2316437B1 (en) * 2005-05-13 2014-07-30 Alza Corporation Multilayer drug delivery system with barrier against reservoir material flow
US20080188510A1 (en) * 2005-05-23 2008-08-07 Eisai R & D Management Co., Ltd. Novel methods using zonisamide
JP2009508903A (ja) * 2005-09-22 2009-03-05 ガラントス ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング 認知障害を伴う疾患の治療に用いるための脳血液関門透過性が改善されたコリン作用増強剤
US20090253654A1 (en) 2005-09-22 2009-10-08 Galantos Pharma Gmbh Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
EP1777222A1 (en) 2005-09-22 2007-04-25 Galantos Pharma GmbH Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
WO2007035941A2 (en) * 2005-09-23 2007-03-29 Alza Corporation Transdermal galantamine delivery system
ES2463715T3 (es) 2008-04-14 2014-05-29 Neurodyn Life Sciences Inc. Derivados de galantamina como profármacos para el tratamiento de enfermedades del cerebro humano
MX2012000939A (es) * 2009-07-23 2012-06-08 Shire Llc Profarmacos de peptidos y aminoacidos de galantamina y usos de los mismos.
WO2013160728A1 (en) 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Dual targeting compounds for the treatment of alzheimer's disease
EP3628315A1 (en) 2018-09-28 2020-04-01 Université de Caen Normandie Combination of acetylcholinesterase inhibitor and 5-ht4 receptor agonist as neuroprotective agent in the treatment of neurodegenerative diseases
CN113292420A (zh) * 2021-05-27 2021-08-24 神隆医药（常熟）有限公司 加兰他敏中间体原料2-溴-5-羟基-4-甲氧基苯甲酸回收方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL122665B1 (en) 1978-11-21 1982-08-31 Edinen Zentar Chim Process for preparing novel dienones of narvedine type and their derivatives
US4663318A (en) 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
US6150354A (en) * 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
AU632458B2 (en) * 1987-05-04 1993-01-07 Bonnie Davis Compounds for the treatment of alzheimer's disease
NL8800350A (nl) 1988-02-12 1989-09-01 Stichting Biomedical Research Synthetische galanthamine-derivaten, werkwijze voor het bereiden daarvan, en farmaceutische samenstellingen.
DK0584185T3 (da) 1991-05-14 2000-02-07 Ernir Snorrason Behandling af træthedssyndrom med cholinesteraseinhibitorer
US5231093A (en) * 1991-10-01 1993-07-27 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
US5153193A (en) 1991-10-01 1992-10-06 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs

Also Published As

Publication number Publication date
AU696249B2 (en) 1998-09-03
DE69429708T2 (de) 2002-08-29
PL177730B1 (pl) 2000-01-31
PT653427E (pt) 2002-06-28
FI944821A0 (fi) 1994-10-13
EP0653427A1 (en) 1995-05-17
IL111274A (en) 2000-11-21
CN1039911C (zh) 1998-09-23
TW363969B (en) 1999-07-11
EP0653427B1 (en) 2002-01-23
ATE212348T1 (de) 2002-02-15
CN1111245A (zh) 1995-11-08
FI108723B (fi) 2002-03-15
RO114133B1 (ro) 1999-01-29
CA2118174C (en) 2000-01-18
JPH07188240A (ja) 1995-07-25
CZ287071B6 (en) 2000-08-16
CZ254694A3 (en) 1995-09-13
DK0653427T3 (da) 2002-04-15
DE69429708D1 (de) 2002-03-14
EG20472A (en) 1999-05-31
KR0169114B1 (ko) 1999-01-15
CA2118174A1 (en) 1995-04-16
NO310415B1 (no) 2001-07-02
IL111274A0 (en) 1994-12-29
NO943893D0 (no) 1994-10-14
US5777108A (en) 1998-07-07
RU2114850C1 (ru) 1998-07-10
RU94036448A (ru) 1996-09-10
FI944821A (fi) 1995-04-16
EP1020470A2 (en) 2000-07-19
AU7581494A (en) 1995-05-04
NO943893L (no) 1995-04-18
NZ264683A (en) 1998-03-25
US6323195B1 (en) 2001-11-27
EP1020470A3 (en) 2000-07-26
ZA948062B (en) 1995-06-06
JP2664344B2 (ja) 1997-10-15
PL305456A1 (en) 1995-04-18
ES2171428T3 (es) 2002-09-16

Similar Documents

Publication Publication Date Title
KR950011443A (ko) 갈란타민 유도체, 이의 제조방법 및 약제로서의 이의 용도
KR930700490A (ko) 탄산탈수효소 억제제로서 유용한 티오펜 설폰아미드
KR950010890A (ko) 폐경기 증후군의 치료방법
KR950017957A (ko) 3, 4, 4-삼치환-피페리디닐-n-알킬카르복실레이트의 제법 및 중간체
KR950010888A (ko) 평활근세포 증식 및 재발협착증을 억제하는 방법
KR950010893A (ko) 자궁내막증 억제 방법
KR950010892A (ko) 자궁 섬유증 억제 방법
MX9207494A (es) 4(5)-amino-1,8-naftiridinas substituidas, procedimiento para su preparacion y composiciones farmaceuticas que las contienen.
KR950011444A (ko) 갈란타민 유도체, 이의 제조방법 및 약제로서의 이의 용도
KR950016723A (ko) 자가면역 질병의 억제 방법
KR900016137A (ko) 면역 억제제로서 유용한 4-퀴놀린 카복실산 유도체
KR950016727A (ko) 트롬보모듈린 발현을 증가시키는 방법
KR950010889A (ko) 혈관형성 및 혈관형성성 질병을 억제하는 방법
KR950011445A (ko) 갈란타민 유도체, 이의 제조방법 및 약제로서의 이의 용도
KR950700255A (ko) 피리딘카르복시이미드아미드 화합물 및 그 용도(pyridinecarboximidamide compounds and the use thereof)
KR950000663A (ko) 트리테르펜 유도체 및 이를 함유하는 엔도텔린-수용체 길항물질
KR930016436A (ko) 4, 13-디옥사바이사이클로[8.2.1]트리데세논유도체와 그의 제조방법, 그의 제조를 위한 중간체 및 이화합물이 함유된 약학조성물
KR950016733A (ko) 난소 발육부전, 사춘기 지연, 또는 성적 유치증의 억제방법
KR910004191A (ko) 신질환치료제
KR910004193A (ko) 안질환 치료용 5-메틸-이속사졸-4-카르복실산 아닐리드 및 2-하이드록시에틸리덴-시아노아세트산 아닐리드
KR950703941A (ko) 일산화질소 합성 억제제(nitrogen monoxide synthesis inhibitor)
KR900012925A (ko) 인돌 유도체
KR960003719A (ko) 녹내장 치료제 및 안압 강하제
KR890008148A (ko) 새로운 세파로스포린 화합물 및 항균제
KR930702339A (ko) 에폭시숙시남산 유도체

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20120924

Year of fee payment: 15

FPAY Annual fee payment

Payment date: 20130926

Year of fee payment: 16

FPAY Annual fee payment

Payment date: 20140923

Year of fee payment: 17